
Opinion|Videos|June 5, 2024
Evolving Commercialization and Distribution Models for PDTs
The panel discusses the challenges of delivering prescription digital therapeutics (PDTs) to patients, challenges caused by PDTs being considered behavioral health benefits, pharmacy benefits, medical benefits, and durable medical equipment benefits.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Medicaid Work Requirements Set to Leave Millions Without Insurance
2
AMCP Nexus 2025: Advancing Health Policy and Patient Outcomes Together
3
Most Favored Nation Drug Pricing Moves Forward, but Experts Warn Details Are Still Missing
4
Changing Tumor Classifications May Explain Rise in Early-Onset CRC
5
















































